Data suggest antibody's clinical benefit in treatment of Alzheimer's disease

A year of monthly infusions of the human monoclonal antibody aducanumab reduced amyloid‐ß (Aß) plaques in patients with prodromal or mild Alzheimer's disease, and resulted in a slowing of clinical decline in these patients, a new study has found. These results, published in the September 2016 issue of Nature, support the continued development of aducanumab as a disease‐modifying treatment for Alzheimer's disease, the researchers stated.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Geriatric Psychiatry Source Type: research